Approved for To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, at least one including bevacizumab. 12.1 Mechanism of Action Relacorilant is a reversible glucocorticoid receptor (GR) antagonist. In functional in vitro assays with the mineralocorticoid receptor, relacorilant showed no agonist or… Side effects,…
Loading full data from Know Your Drugs Institute…